Presentation on theme: "1 CTI Life Sciences Fund Introduction January 2008."— Presentation transcript:
1 CTI Life Sciences Fund Introduction January 2008
2 CTI Life Sciences Fund - Raison D'être "Where broad Operational and VC experience come together to create and realize shareholder value in Canadian Life Sciences Companies with pre-clinical and clinical drugs, drug enabling technologies and medical devices.
3 CTI Life Sciences Fund – People Jean-François Leprince -Managing Partner Accomplished leader with 30 years of multi-products, multifunctional, multi-geographical experience in the pharmaceutical industry Richard Meadows-Managing Partner VC experience in two multi-billion dollar private equity funds along with 15+ years Business Development experience in the pharmaceutical industry Ken Pastor General Partners Representative 20 years experience in the financial market Shermaine Tilley – Principal 20 years experience in the biotech industry, including investment management, consulting, tech transfer and strong academic experience
4 CTI Life Sciences Fund - Investment Objectives Financial objectives High Returns Strategic objectives Value Creation through Pre- clinical/POC Process M&A Exits Goal: Achieve IRRs commensurate with ability to execute strategy DRUGS, DRUG ENABLING TECHNOLOGIES, MEDICAL DEVICES CRITICAL SUCCESS FACTORS Scientific Innovation Entrepreneurship/ Leadership Partnering with U.S. VCs Interacting with Big Pharmas/ Biotechs Positioning for Exits
5 CTI Life Sciences Fund - Investment Strategy Picking the "right" Value Inflection Points Size of round: $5-15M Pre-Money $10-20M Post-Money: $15-35M Bump Up: 2-3 x Size of round: $1-5M Pre-Money $5-10M Post-Money: $6-15 M Size of round: $25-50M Pre-Money $50-100M+ Post-Money: $ M Bump Up: 3-5 x Ph III to market (NDA)
6 CTI Life Sciences Fund Portfolio Companies Biopharmaceuticals Business Description Development Stage Location Cervelo Development of Neuropathic, mixed and inflammatory pain compounds Phase II Mississauga Ontario Chlorion Pharma Development of Neuropathic pain and Epilepsy compounds Pre-Clinical Laval Québec Enobia Pharma Enzyme Replacement Therapy, Hypophosphatasia as lead program Pre-Clinical Montréal Québec TargeGen Leader in kinase inhibitors, applications in Opthamology, myeloproliferative diseases and inflammation Phase II San Diego U.S.A. Lead/Co-Lead Active Follower
7 CTI Life Sciences Fund Overview Emphasis on Quebec & Canadian life sciences companies, U.S. market opportunistically. Emphasis on Quebec & Canadian life sciences companies, U.S. market opportunistically. A highly experienced investment team. A highly experienced investment team. A unique pro-active exit strategy A unique pro-active exit strategy Through active post investment management. Through active post investment management. Leveraging relationships with top advisors and US VC investors to position companies for successful exits. Leveraging relationships with top advisors and US VC investors to position companies for successful exits. M&As vs. I.P.Os. M&As vs. I.P.Os. First Close: CAD $71 million, June First Close: CAD $71 million, June Target size: CAD $100 million, Achieved March Target size: CAD $100 million, Achieved March